Division of Nephrology
More

Recent Publications

Anupam Agarwal, M.D. 
  1. Wright, MM, Schopfer FJ, Baker PRS, Vidyasagar V., Powell P, Chumley P, Iles KE, Freeman BA, Agarwal, A. Fatty acid transduction of nitric oxide signaling: Nitrolinoleic acid potently activates endothelial heme oxygenase-1 expression.Proc Natl Acad Sci, USA, 2006; 103:4299-4304.
  2. Hock TD, Liby K, Wright MM, McConnel S, Schorpp-Kistner M, Ryan TM, Agarwal A. JunB and JunD regulate human heme oxygenase-1 expression in renal epithelial cells. J Biol Chem 2007;282-6875-86. 
  3. Deshane J, Shen S, Chen B, Callabero S, Grochot-Przeczek A, Was H, Li Calzi S, Radoslaw L, Hock TD, Hill-Kapturczak N, Siegal GP, Dulak J, Jozhowicz A, Grant M, Agarwal A. Stromal cell-derived factor-1 promotes angiogenesis via a heme oxygenase-1 dependent mechanism. J Exp Med, 2007;204:605-618. 

Michael Allon, M.D.

  1. Lee H-W, Allon M. When Should a Patient Receive an Arteriovenous Graft Rather Than a Fistula? Seminars in Dialysis. Editorial 2012 Nov 22. [Epub ahead of print] 

Daniel Balkovetz, M.D., Ph.D.

  1. Panwar B, Johnson VA, Patel M, Balkovetz DF. Risk of Vancomycin-Induced Nephrotoxicity in the Population with Chronic Kidney Disease. Am J Med Sci 2012; 0(0):1–4. 

Emmy Bell, M.D.

  1. Bell, EK, Gao L, Judd, S, Glasser, SP, McClellan, W, Gutierrez OM, Safford M, Lacklands DT, Warnock  DG, Muntner P. Blood Pressure Indexes and End-Stage Renal Disease Risk in Adults With Chronic Kidney Disease. American Journal of Hypertension, 2012; 25:789-796.

Suzanne Bergman, M.D.

  1. Bergman SM. Morbidity of Patients with Tunneled Catheters. Jj Am Soc Nephrol. 12:1450, 2001.
  2. Cross S, Bergman SM. Calciphylaxis: A Disease of Excessively Obese Women on Dialysis. J Am Soc Nephrol. 12:1924,2001.

Sumant Chugh, M.D.

  1. Clement L, Liu G, Perez-Torres I, Kanwar YS, Avila-Casado C and Chugh SS. Early changes in gene expression that influence the course of primary glomerular disease. Kidney Int. 2007;72:337-347.
  2. Chugh SS. Transcriptional regulation of podocyte disease. Transl Res2007;149:237-242.
  3. Liu G, Clement L, Kanwar YS, Avila-Casado C and Chugh SS. ZHX proteins regulate podocyte gene expression during the development of nephrotic syndrome. J Biol Chem 2006, 281;39681-39692.
  4. Liu G, Kaw B, Kurfis J, Rahmanuddin S, Kanwar YS, Chugh SS. Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J Clin Invest 2003;112:209-221.

John Curtis, M.D.

  1. Curtis JJ: Corticosteroids and Kidney Transplantation. Clin J Am Soc Nephrol 1: 07-908, 2006.
  2. Curtis JJ: Protocol biopsy: Today's fine-needle aspiration biopsy. Transplantation84:77-678, 2007.

Robert Gaston, M.D.

  1. Kasiskea BL, McBridec MA, Cornell DL, Gaston RS, Henry ML, Irwin FD, Israni AK,  Metzler NW, Murphy KW, Reed AI, Robert JP, Salkowski N, Snyder JJ, Sweet SC. Report of a Consensus Conference on Transplant Program Quality and Surveillance. American Journal of Transplantation, 2012
  2. Hippen BE, DeMattos A, Cook WJ, Kew CE, Gaston RS. Association of CD20-positive infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 5: 2248-2252, 2005.
  3. Bernatt JL, d'Alessandro AM, Port FK, Bleck TP, Heart SO, Medina J, Rosenbaum SH, Gaston RS, et al. The report of a national conference on donation after cardiat death. Am J. Transplant 6: 281-291, 2006.
  4. Gaston RS, Danovitch GM, Epstein RA, Kahn JP, Matas AJ, Schnitzler MA. Must all living donor compensation be viewed as valuable consideration? Am J Transplant7: 1309-10, 2007.

Orlando Gutierrez, M.D.

  1. Gutierrez OM, Judd SE, Muntner P, Rizk, DV, McClellan WM, Safford MM, Cushman M, Kissela BM, Howard VJ, Warnock, DG. Racial differences in albuminuria, kidney function, and risk of stroke. Neurology. Sep 19 2012.
  2. Rizk DV, Gutierrez O, Levitan EB, et al. Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. Sep 2012;27(9):3482-3488. 

Edgar Jaimes, M.D.

  1. Rezonzew G, Chumley P, Feng W, Hua P, Siegal GP, Jaimes EA.  Nicotine Exposure and the Progression of Chronic Kidney Disease:  Role of the alpha 7-nicotinic acetylcholine receptor. American Physiological Society, doi: 10.1152/ajprenal.00661.2011.

Guarav Jain, M.D.

  1. Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI Associated with Synthetic Cannabinoids: A Case Series. Clin J Am Soc Nephrol. 2012 Dec 14. [Epub ahead of print]
  2. Wang HE, Jain G, Glassock RJ and Warnock DG. Comparison of absolute serum creatinine changes versus Kidney Disease: Improving Global Outcomes consensus definitions for characterizing stages of acute kidney injury. Nephrol Dial Transplant. 2013; pp. 1-7.

Bruce Julian, M.D.

  1. Tamouza H, Chemouny JM, Kafkova LR, Berthelot L, Flamant M, Demion M, Mesnard L, Paubelle E, Walker F, Julian BA, Tissandié E, Tiwari MK, Camara NO, Vrtovsnik F, Benhamou M, Novak J, Monteiro RC, Moura IC:  The IgA1 immune complex mediated activatio of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.  Kidney Int 2012 Sep 5. doi: 10.1038/ki.2012.192. [Epub ahead of print] PMID: 22951891
  2. Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, Novak L, Matousovic K, Novak J.  IgA Nephropathy: Molecular Mechanisms of the Disease.  Annu Rev Pathol. 2012, Oct 18; 217-240.
  3. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J:  Autoantiodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.  J Am Soc Nephrol 2012; 23:1579-87. PMID: 22904352
  4. Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cuis D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Krisiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG.  Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLOS Genetics, 2012; 8:1-16.
  5. Hastings MC, Afshan S, Sanders JT, Kane O, Eison TM, Lau KK, Moldoeanu Z, Julian BA, Novak J, Wyatt RJ. Serum Galactose-Deficient IgA1 Level Is Not Associated with Proteinuria in Children with IgA Nephropathy. International Journal of Nephrology, 2012, Article ID 315467, 1-7.
  6. Chandrakantan A, Ratanapanichkich P, Said M, Barker CV, Julian BA. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil. Nephrol Dial Transplant 20:1214-1221, 2005.
  7. Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Tomino Y, Mestecky J, Novak J. IgA1-secreting cells lines from patients with IgA nephropathy produce aberrantly-glycosylated IgA1. J Clin Invest 118:000-000, 2008.

Clifton Kew II, M.D.

  1. Kew II CE, Lopez-Ben R, Smith JK, Robbin ML, Cook WJ, Gaston RS, Deierhoi MH, Julian BA. Posttransplant Lymphoproliferative Disorder Localized Near the Allograt in Renal Transplantation. Transplantation 2000 (March 15): Vol 69: No 5: pp809-814.
  2. Young CJ, Kew II CE. Health Disparities in Transplantation: Focus on the Complexity and Challenge of Renal Transplantation in African-Americans. Medical Clinics of North America. 89(2005) 1003-1031.

Vinetta Kumar, M.D.

  1. A.K. Diehl, V. Kumar, Gateley A, Appleby J.L., O'Keefe M.E. Predictors of Final Speciality Choice by Internal Medicine Residents J Gen Intern Med 2006;21:1045-1049.
  2. Iozzo P, Pratipanawatr T, Pijl H, Vogt C, Kumar V, Pipek R, Matsuda M. Mandarino LJ, Cusi KJ, DeFonzo RA. Physiologic hyperinsulinemia impairs insulin-stimulated glycogen synthetase activity and glycogen synthesis. American Journal of Physiology-Endocrinology & Metabolis 2001 May; 280(5): E712-9.

Roslyn Mannon, M.D.

  1. Sam WJ, Chamberlain CE, Lee SJ, Goldstein JA, Hale DA, Mannon RB, Kirk AD, Hon YY.  Associations of Abcb1 and IL-10 Genetic Polymorphisms with Siroimus-Induced Dyslipidemia in Renal Transplant Receipients. pp 1-32. 

Michal Mrug, M.D.

  1. Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB: Urinary proteomic biomarkers enable diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multi-centric study. PlosOne 2012 (accepted for publication)
  2. Dawoud D, Lyndon W, Mrug S, Bissler JJ, Mrug M.  Impact of ultrasound-guided kidney biopsy simulation on trainee confidence and biopsy outcomes. Am J Nephrol 2012 (accepted for publication).
  3. Sharma N, Malarkey EB, Berbari NF, O’Connor AK, Vanden Heuvel GB, Mrug M, Yoder BK: Proximal tubule proliferation is insufficient to induce rapid cyst formation following cilia disruption. J Am Soc Nephrol, 2013; 24:1-9.

Ji-Bin Peng, Ph.D.

  1. Na T, Wu G, Zhang W, Dong WJ, Peng JB. Disease-causing R1185C mutation of WNK4 disrupts a regulatory mechanism involving calmodulin binding and SGK1 phosphorylation sites. Am J Physiol Renal Physiol. 2012 Oct 10. [Epub ahead of print]. PMID: 23054253. 

Mary Prendergast, M.D.

  1. Prendergast M & Tolwani A: A Simple Trisodium Citrate Protocol that Provides Metabolic Control and High Solute Clearance in Continuous Renal Replacement Therapy. Journal of Investigative Medicine, Vol 52, #1. January 2004 (abstract publication).
  2. Ashita J. Tolwani, Mary B Prendergast, et al: A Practical Citrate Anticoagulation Continueous Venovenous Hemodiafiltration Protocol for Metabolic Control and High Solute Clearance. Clinical Journal American Society of Nephrology (CJASN) 1:79-87, 2006.
  3. Stephen Rostand, M.D
  4. SG Rostand, SP Cliver, RL Goldenberg. Racial Disparities in the Association of Fetal Growth Retardation to Childhood Blood Pressure. Nephrol Dial Transplant2005; 20: 1592-1597.
  5. Gail E. Peterson, MD, Tine de Baker, MD, Avril Gabriel*, Vladimir Ilic, MD, Tudor Vagaonescu, MD, Larry Appel, MD, MPH, Gabriel Contreras, MD, Cindy Kendrick,Stephen Rostand, MD, and Robert Phillips, MD, Ph.D. Prevalence and Correlates of Left Ventricular Hypertrophy in the African American Study of Kidney Disease Cohort Study. Hypertension. 2007; 50:1-7.

Dana Rizk, M.D.

  1. Levitan EB, Gamboa C; Safford MM, Rizk DV; Brown TM; Soliman EZ; Muntner P. Cardioprotective medication use and risk factor control among US adults with unrecognized myocardial infarction: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Vascular Health and Risk Management 2013:9; pp. 47–55. 
  2. Zuber K, Davis J, Rizk DV. Kidney Disease Education One Year after the Medicare Improvement of Patients and Providers Act: A Survey of US Nephrology Practices.  American Journal of Kidney Diseases.  2012, 59:892-894.

Stephen Rostand, M.D.

  1. Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, Contreras G, Gabbai F, Hiremath L, Jamerson K, Kendrick C, Kusek JW, Lash JP, Lea J, Miller III, ER, Rostand S, Toto R, Wang X, Wright Jr, JT, Appel LJ.  A Trial of 2 Strategies to Reduce Nocturnal Blood Pressure in Blacks With Chronic Kidney Disease. Hypertension. 2013; 61:82-88. 

Edwin Rutsky, M.D.

  1. Evans RW, Rader B, Manninen DL and the Cooperative Multicenter EPO Clinical Trial Group. the quality of life of hemodialysis recipients treated with recombinant humanerythropoietin. JAMA 1990: 263:825-830.
  2. Rutsky EA, Dubovsky EV, Kirk KA. Long-term follow-up of a human subject with a remnant kidney. Am J Kidney Dis 1991: 18:509-513.

Paul Sanders, M.D. 

  1. Zarjou A, Guo L, Sanders PW, Mannon RB, Agarwal A, George JF. A reproducible mouse model of chronic renal allograft nephropathy with vasculopathy. Kidney International, 2012. In press. NIHMS390755

Denyse Thornley-Brown, M.D.

  1. Lowenthal EA, Mayo MS, Cornwell PE, and Thornley-Brown D. Homocysteine elevation in sickle cell disease. Journal of the American College of Nutrition 2000, 19:608-612.
  2. Lewis J, Agodoa L, Cheek D, and the African American Study of Hypertension and Kidney Disease. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. American Journal of Kidney Disease 2001, 38:744-753.
  3. Rostand SG, Thornley-Brown D. Soft tissue calcifation in chronic renal failure, in TB Drueke and I. Salusky, eds. the Spectrum of Renal Osteodystrophy (Oxford Clinical Nephrology Series) London, Oxfort University Press, 2001.

Ashita Tolwani, M.D.

  1. Tolwani A.  Continuous Renal-Replacement Therapy for Acute Kidney Injury.  NEJM 2012; 367:2505-14.
  2. Tumlin JA, Chawla L, Tolwani AJ, Mehta R, Dillion J, Finkel KW, DaSilva JR, Astor BC, Yevzlin AS, Humes HD.  The Effect of the Selective Cytopheretic Device on Acute Kidney Injury Outcomes in the Intensive Care Unit: A Multicenter Pilot Study. Seminars in Dialysis. 2012 Oct 29 [Epub ahead of print] 
  3. Tolwani AJ, Wille KM. Advances in Continuous Renal Replacement Therapy:  Citrate Anticoagulation Update. Advances in Technology Blood Purification. October 24, 2012, 34:88-93
  4. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA. Contineous renal replacement therapy: A worldwide practice survey: The Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators. Intensive Care Med; 208;9:1563-70.
  5. Tolwani A, Prendergast M, Speer R, Stofan B, Wille K. A practical anticoagulation CVVHDF protocol for metabolic control and high solute clearance. CJASN 2006 January;1:79-87.

Eric Wallace, M.D.

  1. Wallace E, Day M, Fadare O, Schaefer H. Pathologic Femur Fracture Due to a Brown          Tumor in a Patient with Secondary Hyperparathyroidism and Vitamin D-Resistant Rickets. American Journal of Kidney Disease. 2012; 1-5.

David G. Warnock, M.D.

  1. Acharya D, Robertson P, Neal Kay G, Jackson L, Warnock, DG, Plumb VJ, Tallaj JA.   Arrhythmias in Fabry Cardiomyopathy. Clin Cardiol. Aug 9 2012.
  2. Crews DC, McClellan WM, Shoham DA, Gao L, Warnock DG, Judd S, Muntner P, Miller ER, Powe NR. Low Income and Albuminuria Among REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study Participants. Am J Kidney Dis, 2012, [Epub ahead of print].
  3. Gutierrez OM, Judd SE, Muntner P, Rizk, DV, McClellan WM, Safford MM, Cushman M, Kissela BM, Howard VJ, Warnock, DG. Racial differences in albuminuria, kidney function, and risk of stroke. Neurology. Sep 19 2012.
  4. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, Rossing P, Sarnak MJ, Stengel B, Yamagishi K, Yamashita K, Zhang Z, Coresh J, de Jong PE, Astor BC, for the Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. The Lancet. 2012 Nov 10; 380(9854):1649-61.
  5. Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, Lee JB, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen C-P, Nelson RG, for the Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. The Lancet. 2012 Nov 10; 380(9854):1662-73.
  6. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JFH, Astor BC, Gansevoort RT, Levin A, Wen C-P, Coresh J, for the Chronic Kidney Disease. Age and Association of Kidney Measures With Mortality and End-stage Renal Disease for the Chronic Kidney Disease. JAMA. 2012 Dec 12; 308(22):2349-60.